HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van den Hoek, A. M. Articles by Pijl, H. Search for Related Content PubMed PubMed Citation Articles by van den Hoek, A. M. Articles by Pijl, H. Social Bookmarking                What's this?

PYY_3–36 Reinforces Insulin Action on Glucose Disposal in Mice Fed a High-Fat Diet

¹ TNO Prevention and Health, Gaubius Laboratory, Leiden, the Netherlands
² Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands
³ Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, the Netherlands
⁴ Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands

Peptide YY_3–36 (PYY_3–36) is released by the gut in response to nutrient ingestion. It modulates the activities of orexigenic neuropeptide Y (NPY) neurons and anorexigenic proopiomelanocortin (POMC) neurons in the hypothalamus to inhibit food intake. Because both NPY and POMC have also been shown to impact insulin action, we wondered whether PYY_3–36 could improve insulin sensitivity. To address this question, we examined the acute effect of intravenous PYY_3–36 on glucose and free fatty acid (FFA) flux during a hyperinsulinemic-euglycemic clamp in mice maintained on a high-fat diet for 2 weeks before the experiment. We also evaluated the effects of PYY_3–36 infusion on glucose uptake in muscle and adipose tissue in this experimental context. Under basal conditions, none of the metabolic parameters were affected by PYY_3–36. Under hyperinsulinemic conditions, glucose disposal was significantly increased in PYY_3–36-infused compared with vehicle-infused mice (103.8 ± 10.9 vs. 76.1 ± 11.4 µmol · min^–1 · kg^–1, respectively; P = 0.001). Accordingly, glucose uptake in muscle and adipose tissue was greater in PYY_3–36- treated animals, although the difference with controls did not reach statistical significance in adipose tissue (muscle: 2.1 ± 0.5 vs. 1.5 ± 0.5 µmol/g tissue, P = 0.049; adipose tissue: 0.8 ± 0.4 vs. 0.4 ± 0.3 µmol/g tissue, P = 0.08). In contrast, PYY_3–36 did not impact insulin action on endogenous glucose production or FFA metabolism. These data indicate that PYY_3–36 reinforces insulin action on glucose disposal in mice fed a high-fat diet, through a mechanism that is independent of food intake and body weight. In contrast, it leaves glucose production and lipid flux largely unaffected in this experimental context.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. A. Ortiz, L. F. Milardo, L. B. DeCarr, T. M. Buckholz, M. R. Mays, T. H. Claus, J. N. Livingston, C. D. Mahle, and K. J. Lumb A Novel Long-Acting Selective Neuropeptide Y2 Receptor Polyethylene Glycol-Conjugated Peptide Agonist Reduces Food Intake and Body Weight and Improves Glucose Metabolism in Rodents J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 692 - 700. [Abstract] [Full Text] [PDF]

				S. Vidarsdottir, P. A.M. Smeets, D. L. Eichelsheim, M. J.P. van Osch, M. A. Viergever, J. A. Romijn, J. van der Grond, and H. Pijl Glucose Ingestion Fails to Inhibit Hypothalamic Neuronal Activity in Patients With Type 2 Diabetes Diabetes, October 1, 2007; 56(10): 2547 - 2550. [Abstract] [Full Text] [PDF]

				P. A. M. Smeets, S. Vidarsdottir, C. de Graaf, A. Stafleu, M. J. P. van Osch, M. A. Viergever, H. Pijl, and J. van der Grond Oral glucose intake inhibits hypothalamic neuronal activity more effectively than glucose infusion Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E754 - E758. [Abstract] [Full Text] [PDF]

				A. M. van den Hoek, A. C. Heijboer, P. J. Voshol, L. M. Havekes, J. A. Romijn, E. P. M. Corssmit, and H. Pijl Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E238 - E245. [Abstract] [Full Text] [PDF]

				E. Naslund and J. G. Kral Impact of Gastric Bypass Surgery on Gut Hormones and Glucose Homeostasis in Type 2 Diabetes Diabetes, December 1, 2006; 55(Supplement_2): S92 - S97. [Abstract] [Full Text] [PDF]

				M. A. M. den Boer, P. J. Voshol, J. P. Schroder-van der Elst, E. Korsheninnikova, D. M. Ouwens, F. Kuipers, L. M. Havekes, and J. A. Romijn Endogenous Interleukin-10 Protects against Hepatic Steatosis but Does Not Improve Insulin Sensitivity during High-Fat Feeding in Mice Endocrinology, October 1, 2006; 147(10): 4553 - 4558. [Abstract] [Full Text] [PDF]

				M. Misra, K. K. Miller, P. Tsai, K. Gallagher, A. Lin, N. Lee, D. B. Herzog, and A. Klibanski Elevated Peptide YY Levels in Adolescent Girls with Anorexia Nervosa J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1027 - 1033. [Abstract] [Full Text] [PDF]

				S. H. Adams, C. Lei, C. M. Jodka, S. E. Nikoulina, J. A. Hoyt, B. Gedulin, C. M. Mack, and E. S. Kendall PYY[3-36] Administration Decreases the Respiratory Quotient and Reduces Adiposity in Diet-Induced Obese Mice J. Nutr., January 1, 2006; 136(1): 195 - 201. [Abstract] [Full Text] [PDF]

				S. S. Torekov, L. H. Larsen, C. Glumer, K. Borch-Johnsen, T. Jorgensen, J. J. Holst, O. D. Madsen, T. Hansen, and O. Pedersen Evidence of an Association Between the Arg72 Allele of the Peptide YY and Increased Risk of Type 2 Diabetes Diabetes, July 1, 2005; 54(7): 2261 - 2265. [Abstract] [Full Text] [PDF]